3149 Real-world Australian experience with Ofatumumab in the MSBase registry

• Published in: BMJ neurology open Vol. 6; no. Suppl 1; pp. A45 - A46
• Main Authors: Migocki, Margaret, Walt, Anneke Van der, Butzkueven, Helmut, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M, Lechner-Scott, Jeannette, John, Nevin, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Kalincik, Tomas, Macdonell, Richard, Slee, Mark, Schmitt, Birte
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd 01-08-2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Poster Abstracts; Australia
• ISSN: 2632-6140
• DOI: 10.1136/bmjno-2024-ANZAN.127

ObjectivesTo characterize the use of ofatumumab (OFA), a fully human self-administered anti-CD20 monoclonal antibody, in a real-world setting in Australia by assessing the profile of relapsing multiple sclerosis (RMS) patients initiating OFA through an evaluation of patient demographics, background MS disease characteristics and prior therapy history as recorded in MSBase.MethodsThis is a retrospective secondary use of MSBase Registry data study, describing the baseline characteristics of RMS patients in Australia initiated on OFA treatment, including demographics, disease duration, expanded disability status scale (EDSS), treatment history with disease-modifying therapies (DMTs) prior to commencing OFA and proportion of naïve patients initiating ofatumumab relative to patients having received a prior DMT.ResultsAs of 1st January 2024, MSBase has included 320 eligible patients initiated on OFA, with 22.2% treatment naïve, 30.9% switching from ocrelizumab, 14.7% switching from natalizumab, 3.1% from alemtuzumab and 27.7% from oral DMTs. The reasons for switching DMT to OFA included scheduled stop (13.1%), evidence of disease activity (9.1%), convenience (6.9%), side effects/intolerance (6.2%), JCV antibody positive (2.8%), pregnancy planned/confirmed (2.5%) and not reported (37.2%). The median age of patients initiating OFA was 42.67 [36.65, 51.98] years, with a median disease duration of 9.19 [3.61, 17.11] years and median EDSS of 2 [1.5, 3.5].ConclusionThe real-world data from this secondary use of data MSBase registry analysis provides a valuable snapshot of the Australian experience of relapsing MS patients initiated on OFA, with 22% of patients treated as first line therapy.